tenofovir has been researched along with acyclovir in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (33.33) | 29.6817 |
| 2010's | 14 (58.33) | 24.3611 |
| 2020's | 2 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Alvarez, K; Balzarini, J; Barral, K; Canard, B; Neyts, J; Priet, S; Sire, J | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
| Agrofoglio, LA; Alexandre, JA; Andrei, G; Azzouzi, A; Balzarini, J; Broggi, J; Caillat, C; Deville-Bonne, D; El-Amri, C; Eriksson, S; Lin, J; Meyer, P; Pradère, U; Roy, V; Snoeck, R; Topalis, D | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Andrei, G; Buckheit, RW; De Jonghe, S; Groaz, E; Hartman, T; Herdewijn, P; Kalkeri, R; Luo, M; Ptak, RG; Schols, D; Snoeck, R | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| De Clercq, E; Neyts, J; Ying, C | 1 |
| De Clercq, E; Furman, P; Neyts, J; Nicholson, W; Ying, C | 1 |
| Cohen, J | 1 |
| De Clercq, E | 2 |
| Baum, MM; Butkyavichene, I; Clark, MR; Friend, DR; Gilman, J; Kennedy, S; Kopin, E; Malone, AM; Moss, JA; Motamedi, M; Nguyen, C; Smith, TJ; Vincent, KL | 1 |
| Baum, MM; Butkyavichene, I; Clark, MR; Friend, DR; Gilman, J; Kennedy, S; Kopin, E; Malone, AM; Moss, JA; Nguyen, C; Smith, TJ | 1 |
| Alt, C; Shankar, GN | 1 |
| Ceña-Diez, R; de la Mata, FJ; García-Broncano, P; Gómez, R; Maly, M; Muñoz-Fernández, MÁ; Vacas-Córdoba, E | 1 |
| Feng, B; Litchfield, J; Mathialagan, S; Piotrowski, MA; Tess, DA; Varma, MV | 1 |
| Andrei, G; Gillemot, S; Snoeck, R; Topalis, D | 1 |
| To, EE | 1 |
5 review(s) available for tenofovir and acyclovir
| Article | Year |
|---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The discovery of antiviral agents: ten different compounds, ten different stories.
Topics: Acyclovir; Adenine; Antiviral Agents; Benzodiazepines; Benzylamines; Cidofovir; Cyclams; Cytosine; Heterocyclic Compounds; Humans; Imidazoles; Nucleosides; Organophosphonates; Tenofovir; Valacyclovir; Valine; Virus Diseases | 2008 |
Fifty Years in Search of Selective Antiviral Drugs.
Topics: Acyclovir; Antiviral Agents; DNA Virus Infections; DNA Viruses; HIV; HIV Infections; Humans; Molecular Structure; Tenofovir; Valacyclovir | 2019 |
Cell and Tissue Specific Metabolism of Nucleoside and Nucleotide Drugs: Case Studies and Implications for Precision Medicine.
Topics: Acyclovir; Antiviral Agents; Ganciclovir; HIV Infections; Humans; Nucleosides; Nucleotides; Precision Medicine; Tenofovir | 2023 |
19 other study(ies) available for tenofovir and acyclovir
| Article | Year |
|---|---|
Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
Topics: Adenine; Animals; Anti-HIV Agents; Antiviral Agents; Boranes; Boron Compounds; Chlorocebus aethiops; DNA Viruses; HIV-1; Humans; In Vitro Techniques; Nucleosides; Organophosphonates; Phosphates; RNA Viruses; Structure-Activity Relationship; Vero Cells; Virus Replication | 2006 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Topics: Anti-Infective Agents; Antiviral Agents; Artificial Intelligence; Computer Simulation; Drug Evaluation, Preclinical; Molecular Structure; Quantitative Structure-Activity Relationship | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Novel antiviral C5-substituted pyrimidine acyclic nucleoside phosphonates selected as human thymidylate kinase substrates.
Topics: Antiviral Agents; Catalytic Domain; Cells, Cultured; Crystallography, X-Ray; Herpesviridae; Humans; Ligands; Models, Molecular; Molecular Structure; Nucleoside-Phosphate Kinase; Organophosphonates; Prodrugs; Pyrimidine Nucleosides; Stereoisomerism; Structure-Activity Relationship; Substrate Specificity; Thymidine; Thymidine Kinase | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Aspartic Acid; Cell Line; Cytomegalovirus; Drug Resistance, Viral; Drug Stability; Esters; Hepatitis B virus; Herpesvirus 3, Human; Humans; Hydrogen-Ion Concentration; Microsomes, Liver; Nucleosides; Organophosphonates; Prodrugs; Stereoisomerism; Structure-Activity Relationship | 2017 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Lamivudine, adefovir and tenofovir exhibit long-lasting anti-hepatitis B virus activity in cell culture.
Topics: Acyclovir; Adenine; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Guanine; Hepatitis B virus; Lamivudine; Organophosphonates; Organophosphorus Compounds; Tenofovir; Tumor Cells, Cultured | 2000 |
Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir.
Topics: Acyclovir; Adenine; Antiviral Agents; Arabinofuranosylcytosine Triphosphate; Cell Line; Dioxolanes; DNA-Directed DNA Polymerase; DNA, Viral; Guanine; Hepatitis B virus; Humans; Organophosphonates; Organophosphorus Compounds; Purine Nucleosides; Tenofovir; Virus Replication | 2000 |
HIV/AIDS. Prevention cocktails: combining tools to Stop HIV's spread.
Topics: Acyclovir; Adenine; Anti-HIV Agents; Antidepressive Agents, Second-Generation; Antiviral Agents; Bupropion; Circumcision, Male; Clinical Trials as Topic; Contraceptive Devices, Female; Female; Herpes Genitalis; Herpesvirus 2, Human; HIV; HIV Infections; Humans; Hygiene; Male; Organophosphonates; Sexual Behavior; Tenofovir; Viral Load | 2005 |
Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring.
Topics: Acyclovir; Adenine; Administration, Intravaginal; Animals; Anti-HIV Agents; Antiviral Agents; Delayed-Action Preparations; Disease Models, Animal; Drug Combinations; Drug Delivery Systems; Equipment Design; Female; Herpes Genitalis; Herpesvirus 2, Human; HIV Infections; HIV-1; Humans; Organophosphonates; Rabbits; Sexually Transmitted Diseases, Viral; Tenofovir; Treatment Outcome | 2012 |
An intravaginal ring for the simultaneous delivery of multiple drugs.
Topics: Acyclovir; Adenine; Administration, Intravaginal; Animals; Antiviral Agents; Delayed-Action Preparations; Drug Delivery Systems; Equipment Design; Female; HIV; HIV Infections; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Silicon; Tenofovir; Tensile Strength | 2012 |
Prophylactic treatment with a novel bioadhesive gel formulation containing aciclovir and tenofovir protects from HSV-2 infection.
Topics: Acrylic Resins; Acyclovir; Adenine; Animals; Anti-Infective Agents; Chlorocebus aethiops; Disease Models, Animal; Drug-Related Side Effects and Adverse Reactions; Female; Herpes Genitalis; Herpesvirus 2, Human; Mice, Inbred BALB C; Organophosphonates; Poloxamer; Rabbits; Rats, Sprague-Dawley; Tenofovir; Treatment Outcome; Vaginal Creams, Foams, and Jellies; Vero Cells | 2014 |
Prevention of vaginal and rectal herpes simplex virus type 2 transmission in mice: mechanism of antiviral action.
Topics: Acyclovir; Administration, Rectal; Animals; Anti-Infective Agents; Antiviral Agents; Chlorocebus aethiops; Dendrimers; Epithelial Cells; Female; Herpes Simplex; Herpesvirus 2, Human; Humans; Hydrogen-Ion Concentration; Male; Mice, Inbred BALB C; Models, Molecular; Polyelectrolytes; Polymers; Rectum; Silanes; Tenofovir; Vagina; Vero Cells; Viral Proteins | 2016 |
Quantitative Prediction of Human Renal Clearance and Drug-Drug Interactions of Organic Anion Transporter Substrates Using In Vitro Transport Data: A Relative Activity Factor Approach.
Topics: Acyclovir; Anti-Bacterial Agents; Antiviral Agents; Drug Interactions; Ganciclovir; HEK293 Cells; Humans; Kidney; Models, Biological; Organic Anion Transport Protein 1; Organic Anion Transporters, Sodium-Independent; Oseltamivir; Penicillin G; Probenecid; Renal Elimination; Tenofovir; Transfection | 2017 |
The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase.
Topics: Acyclovir; Amino Acid Substitution; Antiviral Agents; Cells, Cultured; DNA Mutational Analysis; DNA-Directed DNA Polymerase; Drug Resistance, Viral; Exodeoxyribonucleases; Foscarnet; Herpes Genitalis; Herpes Simplex; Herpesvirus 1, Human; Herpesvirus 2, Human; Humans; Mutation, Missense; Organophosphonates; Pyrimidines; Reverse Transcriptase Inhibitors; Selection, Genetic; Sequence Analysis, DNA; Tenofovir; Viral Proteins | 2018 |